CHF 5633

Drug Profile

CHF 5633

Alternative Names: CHF5633; Synthetic surfactant - Chiesi

Latest Information Update: 19 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi; Karolinska Institute; Swedish University of Agricultural Sciences
  • Developer Chiesi
  • Class Pulmonary surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neonatal respiratory distress syndrome

Most Recent Events

  • 01 Jan 2016 Phase-II clinical trials in Neonatal respiratory distress syndrome in USA (Intratracheal) (NCT02452476)
  • 26 May 2015 Chiesi plans a phase II trial for Neonatal respiratory distress syndrome in USA (NCT02452476)
  • 01 Feb 2015 Chiesi Farmaceutici completes a phase I trial for Neonatal respiratory distress syndrome in United Kingdom (NCT01651637)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top